Form 4: OrbiMed Advisors Reports Purchases of Disc Medicine Stock

OrbiMed Advisors LLC and related entities report the acquisition of Disc Medicine, Inc. (IRON) common stock through a series of transactions on June 17, 2024.

Summary

• On June 17, 2024, OrbiMed Advisors LLC, along with related entities including OrbiMed Private Investments VI, LP (OPI VI), OrbiMed Private Investments VIII, LP (OPI VIII), and OrbiMed Genesis Master Fund, L.P. (Genesis), acquired shares of Disc Medicine, Inc. (IRON) common stock.
• The purchases were made at a price of $36 per share.
• OPI VI acquired 28,404 shares, bringing its total indirect beneficial ownership to 608,611 shares.
• OPI VIII acquired 43,944 shares, increasing its indirect beneficial ownership to 941,569 shares.
• Genesis acquired 10,986 shares, resulting in a total indirect beneficial ownership of 235,391 shares.
• OrbiMed Advisors, as the managing member of the general partners of OPI VI, OPI VIII, and Genesis, may be deemed to have voting and investment power over these securities.
• Carl L. Gordon, Sven H. Borho, and W. Carter Neild, as members of the management committee of OrbiMed Advisors, disclaim beneficial ownership of the shares held by OPI VI, OPI VIII, and Genesis.
• Mona Ashiya, an employee of OrbiMed Advisors, serves on the Issuer's board of directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The purchases indicate confidence from OrbiMed, but the filing is a routine disclosure.

Positives

• The purchases indicate a potential positive outlook from OrbiMed Advisors regarding Disc Medicine's future performance.
• The increased holdings by OrbiMed's investment funds could signal confidence in the company's prospects.

Risks

• The Form 4 filing does not provide specific reasons for the stock purchases, so the rationale behind the investment is not explicitly stated.
• The members of the management committee of OrbiMed Advisors disclaim beneficial ownership of the shares held by OPI VI, OPI VIII, and Genesis.

Management Comments

• Carl L. Gordon, Sven H. Borho, and W. Carter Neild disclaim beneficial ownership of the shares held by OPI VI, OPI VIII, and Genesis.

Industry Context

Hedge funds and investment firms regularly adjust their holdings in publicly traded companies, and these transactions are disclosed through SEC filings like Form 4. These filings provide insights into the investment strategies and confidence levels of major investors in specific companies and sectors.

Comparison to Industry Standards

• OrbiMed is a well-known healthcare investment firm, and its investment decisions are often closely watched by other investors in the biotechnology and pharmaceutical industries.
• Comparing OrbiMed's holdings and transactions to those of other major healthcare investors like Baker Bros. Advisors or RA Capital Management can provide a broader perspective on market sentiment towards Disc Medicine and its competitors.

Stakeholder Impact

• The increased holdings by OrbiMed could positively influence shareholder confidence.
• The transactions may have a limited impact on employees, customers, suppliers, and creditors unless they signal a significant shift in the company's strategic direction.

Key Dates